Pay in 4 interest-free payments of $6.85 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
How is CVS Caremark supporting customers and members through these changes
Combination Therapies: Novel combination products of insulin and GLP-1 receptor agonists are developed and introduced
IV therapy quickly infuses beneficial substances directly into the bloodstream
In the phase 3 SLIMMER trial published in The Lancet Diabetes & Endocrinology last year, ecnoglutide achieved weight loss of 15.1% at 48 weeks, with no evidence of a plateauing of effect, along with improvements in waist circumference, blood pressure, lipid profile, HbA1c, fasting glucose, and insulin levels
Exp: 06/2028
US$ 21.74
US$ 25.55
US$ 28.10
US$ 28.21
